vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and AMDOCS LTD (DOX). Click either name above to swap in a different company.
AMDOCS LTD is the larger business by last-quarter revenue ($1.3B vs $722.5M, roughly 1.7× Amneal Pharmaceuticals, Inc.). AMDOCS LTD runs the higher net margin — 11.2% vs 10.8%, a 0.4% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (3.9% vs 1.1%). Over the past eight quarters, AMDOCS LTD's revenue compounded faster (4.5% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Amdocs Limited is a multinational telecommunications technology company headquartered in Chesterfield, Missouri. The company specializes in software and services for communications, media and financial services providers and digital enterprises. Amdocs was founded in 1982 and is publicly traded on the Nasdaq stock exchange.
AMRX vs DOX — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $1.3B |
| Net Profit | $78.0M | $140.3M |
| Gross Margin | 44.3% | — |
| Operating Margin | — | 14.1% |
| Net Margin | 10.8% | 11.2% |
| Revenue YoY | 3.9% | 1.1% |
| Net Profit YoY | 217.0% | -12.0% |
| EPS (diluted) | $0.19 | $1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | — | ||
| Q2 25 | $724.5M | — | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | — | ||
| Q2 24 | $701.8M | $1.3B |
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $22.4M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | — | ||
| Q2 24 | $6.0M | $140.3M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | 14.1% |
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | — | ||
| Q2 24 | 0.9% | 11.2% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | $1.21 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
DOX
Segment breakdown not available.
